Compare BFRI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRI | INTS |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | 94 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.9M |
| IPO Year | N/A | 2021 |
| Metric | BFRI | INTS |
|---|---|---|
| Price | $1.11 | $4.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.75 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 374.9K | 64.3K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $16.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.19 |
| 52 Week High | $1.21 | $8.06 |
| Indicator | BFRI | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 66.87 |
| Support Level | $0.77 | $4.50 |
| Resistance Level | $1.13 | $8.06 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 69.94 | 83.34 |
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.